New Alzheimer's Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, and Tolerability
- ANAVEX® Life Sciences Corp.
- Jan 11, 2016
- 1 min read
Alzheimer’s Association International Conference 2016, Toronto, Canada
Steve Macfarlane, Marco Cecchi, Dennis Moore, Paul Maruff, Kristina M. Capiak, Anastasios Zografidis, Christopher U. Missling
